This document discusses the management of valvular regurgitation in patients with cardiomyopathy. It notes that secondary mitral regurgitation is common in end-stage cardiomyopathy and can affect up to 60% of heart failure patients. While medical management focuses on treating the underlying heart failure, the document finds that mitral valve repair with an undersized annuloplasty ring can significantly improve symptoms and survival rates, comparable to heart transplantation. Several studies showed mitral valve repair improved ejection fraction and functional status while carrying an acceptable mortality risk in this high-risk group. The conclusion is that mitral valve surgery should be considered for symptomatic patients with severe secondary mitral regurgitation who remain symptomatic despite medical optimization.